证券研究报告·海外公司点评·药品及生物科技(HS) 药明合联（02268.HK） 2025 年中报点评：业绩超预期，资本开支持 续加码，高成长性确定性强 买入（维持） | Table_EPS] [盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 2,169 | 4,052 | 6,108 | 8,199 | 10,305 | | 同比（%） | 114.26 | 86.82 | 50.72 | 34.24 | 25.68 | | 归母净利润（百万元） | 283.54 | 1,069.62 | 1,596.30 | 1,998.67 | 2,758.31 | | 同比（%） | 82.07 | 277.24 | 49.24 | 25.21 | 38.01 | | Non-GAAP 净利润（百万元） | 412.26 | 1,174.01 | 1,696.30 | 2,198.67 | 2,908.31 | | 同比（%） | 112.10 | 184.77 ...

即时零售与全渠道生态深化，构建"线上健康消费第一入口"。截至 2025 年 6 月底，京东买药秒送链接超 20 万家线下药房，线上医保 支付扩至近 2 亿人口。上半年公司与北京儿童医院打造"双通道" 儿科专属药房，打通处方流转、医保支付与配送闭环。同时，公司 扩大平台商品丰富度，平台商家数量半年增长超过5万家至15万家。 我们认为，京东健康已形成"自营+在线平台+即时零售"相融合的 成熟运营模式，随着线上医保购药陆续放开，公司有望打开中长期 增长空间。 事件：北京时间 2025 年 8 月 14 日，京东健康（06618.HK）发布 2025 年中期未经审计业绩。公司 2025 年上半年实现营业收入 353 亿元， 较去年同期 283 亿元同比增长 24.5%。其中，公司第二季度实现营 业收入 186 亿元，同比增长 23.67%，增速环比一季度持续提升。公 司经营盈利为 21.27 亿元，同比增长 105.5%；非国际财务报告准则 （Non-IFRS）经营盈利为 24.83 亿元，同比增长 56.7%；非国际财务 报告准则（Non-IFRS）盈利为 35.7 亿元，同比增长 35%。 点评： 商品收入稳健， ...

科伦博泰生物-B（06990.HK） 2025 年中报点评：业绩符合预期，核心产品 商业化进展顺利，后续管线多维度展开 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1,540 | 1,933 | 1,943 | 3,560 | 5,894 | | 同比(%) | 91.62 | 25.48 | 0.51 | 83.22 | 65.56 | | 归母净利润（百万元） | (574.13) | (266.77) | (412.63) | (101.95) | 631.68 | | 同比(%) | 6.81 | 53.54 | (54.68) | 75.29 | 719.61 | | EPS-最新摊薄（元/股） | (2.46) | (1.14) | (1.77) | (0.44) | 2.71 | | P/E（现价&最新摊薄） | - | - | - | - | 145.74 | 证券研究报告·海外公司点评·药品 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 12.55 per share, indicating an expected relative return of over 20% within the next six months [5][13]. Core Insights - The company is focusing on the potential of next-generation immuno-oncology therapies, particularly the CS2009 (PD-1/VEGF/CTLA-4) which is expected to show promising efficacy and safety data at the upcoming ESMO conference [2]. - The sales of Pralsetinib have significantly declined due to price adjustments and one-time channel compensations in preparation for national medical insurance negotiations, but successful inclusion in the insurance directory is anticipated to accelerate sales growth post-2026 [1]. - The clinical pipeline is expanding with multiple candidates, including CS5001 (ROR1 ADC), which is progressing steadily through clinical trials and is expected to broaden its indications [3][4]. Summary by Sections Financial Performance - For the first half of 2025, the company reported revenue of RMB 49.4 million, with a significant decline in Pralsetinib sales due to price adjustments [1]. - The revenue and profit forecasts for 2025-2027 have been adjusted, with expected revenues of RMB 123 million, RMB 829 million, and RMB 1.125 billion, reflecting year-on-year growth rates of -68.25%, 575.37%, and 35.81% respectively [5]. Clinical Development - CS2009 is undergoing a global multi-center I/II clinical trial, with safety and efficacy data expected to be presented at the ESMO conference in October 2025 [2]. - CS5001 is actively recruiting patients for various treatment combinations, showing no dose-limiting toxicities (DLT) thus far, and is expected to expand into Phase II studies [3]. Pipeline Expansion - The company has over nine potential candidates in its preclinical pipeline, focusing on multi-specific antibodies and ADCs, which cover oncology, autoimmune, and inflammatory diseases [4].

Investment Rating - The report assigns a "Buy" rating for the company with a target price of 13.07 HKD, based on a 20x PE for 2025 [5]. Core Insights - The company is positioned for accelerated growth through a dual strategy of "independent research and global expansion," which enhances its international transformation potential [1][12]. - In 2024, the company achieved a revenue of 10.784 billion RMB, a year-on-year increase of 10.59%, and a net profit of 2.286 billion RMB, up 31.28% year-on-year, driven by increased demand for core products in nuclear medicine and cardiovascular precision intervention [21]. Summary by Sections 1. Company Overview - Founded in 1939, the company operates across three main sectors: nuclear medicine for tumor diagnosis and treatment, cardiovascular precision intervention, and pharmaceutical technology [1][12]. - The company has over 10,000 employees globally and more than 30 subsidiaries, with a diverse product portfolio exceeding 200 items in the medical insurance directory [1][12]. 2. Pharmaceutical Technology - The company is focused on developing innovative drugs in respiratory and critical care, with STC3141 showing promise as a new treatment for sepsis [2][31]. - The global market for sepsis treatment is projected to grow from 12.54 billion USD in 2024 to 19.37 billion USD by 2032, indicating significant unmet clinical needs [40]. 3. Nuclear Medicine - The company has established a complete industrial chain in nuclear medicine, with its core product, Yttrium-90 microsphere injection, rapidly gaining market traction since its approval in 2022 [3][4]. - The company is advancing multiple nuclear medicine products through clinical trials, including TLX591 for prostate cancer and GPN02006 for liver cancer diagnosis, positioning itself in the global first-tier of development [4][12]. 4. Financial Forecast - Revenue projections for 2025-2027 are 12.405 billion RMB, 13.729 billion RMB, and 15.113 billion RMB, respectively, with net profits expected to be 2.121 billion RMB, 2.396 billion RMB, and 2.773 billion RMB [5].

Investment Rating - The report assigns a "Buy" rating for the company with a target price of 18.63 HKD, based on a current price of 10.36 HKD [6]. Core Insights - The company is positioned as a leading innovative pharmaceutical enterprise in China, with a strong focus on research and development, and a robust commercialization capability [14][19]. - The recent performance has been impacted by price adjustments and centralized procurement policies, but new licensing revenues and additional product launches are expected to drive growth [19][20]. - The company has established eight major technology platforms, showcasing its research capabilities and potential for future growth through international licensing agreements [4][29]. Summary by Sections Company Overview - The company integrates research, production, and sales, focusing on innovative drugs as its core strategy, supported by a large international R&D team and a comprehensive marketing network [14][15]. Financial Performance - In Q1 2025, the company reported revenues of 70.15 billion CNY, a year-on-year decline of 21.9%, with a net profit of 14.95 billion CNY, down 8.3% [20][22]. - The traditional pharmaceutical business, which contributes approximately 80% of total sales, has faced pressure due to centralized procurement and price adjustments [19][22]. Product Pipeline and Innovation - The company has a diverse pipeline with over 200 innovative drugs and formulations, including 10 ADC products in clinical stages, highlighting its strong R&D capabilities [33][39]. - Key products like SYS6010 (EGFR ADC) have entered critical clinical phases, with significant potential for licensing and market impact [2][45]. Market Expansion and Licensing - The company has successfully executed multiple international licensing agreements, enhancing its global presence and generating substantial licensing revenue [35][36]. - Recent collaborations with major pharmaceutical companies, such as AstraZeneca, indicate a growing recognition of the company's innovative capabilities [37][38].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative return of over 20% within the next six months [6]. Core Insights - The company reported a total revenue of 657 million yuan for H1 2025, representing a year-on-year growth of 20%, with a net profit of 328 million yuan, up 59% [1]. - The company has successfully reduced R&D expenses to 228 million yuan, with an R&D expense ratio of 37.25%, down 6 percentage points year-on-year [2]. - The drug Pimiatinib has shown potential as a breakthrough therapy, with a 54% overall response rate (ORR) in a clinical trial, significantly higher than the 3.2% in the placebo group [3]. - The company has initiated a clinical study for ABSK011, a drug targeting FGFR4, which has received breakthrough therapy designation, indicating its potential in treating HCC patients with FGF19 overexpression [4]. - The company is actively developing several pipeline drugs, including ABSK043 and ABSK061, with promising early data [5]. Financial Projections - The company is projected to achieve revenues of 630 million yuan, 684 million yuan, and 634 million yuan for the years 2025, 2026, and 2027, respectively [6]. - The expected net profit for the same years is forecasted to be 45 million yuan, 68 million yuan, and 98 million yuan [6].

Group 1 - The overall valuation of the Hong Kong internet social services sector is currently low, indicating potential upward space [1] - With the rise in AI capital expenditure and increased support for technological innovation policies, leading companies in the technology sector have medium to long-term growth potential [1] - Recent market sentiment has declined significantly, but positive signals from the Political Bureau meeting and policy outlook for the second half of the year suggest that overall policies will remain stable, leading to a continuation of valuation recovery under structural policy guidance [1] Group 2 - The Hong Kong Technology ETF (513020) tracks the Hong Kong Stock Connect Technology Index (931573), which primarily includes listed technology-related companies across nine Hang Seng secondary industries, reflecting the investment characteristics of the integration of technology and consumption [1] - Investors without stock accounts can consider the Cathay CSI Hong Kong Stock Connect Technology ETF Initiated Link A (015739) and Link C (015740) [1]

Investment Rating - The report maintains a "Buy" rating for the company [5][7]. Core Insights - The company's core product, SKB264, is positioned as a promising ADC targeting TROP2, with significant clinical trial progress and potential for commercialization [1][14]. - SKB264 has shown superior efficacy in various clinical settings, particularly in NSCLC, outperforming competitors in terms of mPFS [2][24]. - The collaboration with Merck enhances the global development strategy for SKB264, indicating strong commercial potential [1][15]. Summary by Sections Section 1: Collaboration and Clinical Development - The company has partnered with Merck to develop SKB264, which is currently in multiple Phase III clinical trials for various indications, including NSCLC and triple-negative breast cancer [14][15]. - SKB264 is recognized as a candidate with "blockbuster potential" by Merck, reflecting confidence in its market value [16]. Section 2: Efficacy in NSCLC - In the first-line treatment of wild-type NSCLC, SKB264 demonstrated a median progression-free survival (mPFS) of 15.0 months, significantly better than other TROP2 ADCs [2][24]. - In patients with PD-L1 TPS ≥1%, the mPFS reached 17.8 months, showcasing its effectiveness in this subgroup [2][24]. - SKB264 also exhibited promising results in EGFR-mutated NSCLC patients, with a notable reduction in tumor size compared to standard treatments [3][36]. Section 3: Future Potential and Market Position - The report highlights the potential of combining next-generation immunotherapy with ADCs, positioning SKB264 as a key player in this evolving treatment landscape [4][19]. - The competitive landscape for TROP2 ADCs is intensifying, with SKB264 among the leading candidates, necessitating close monitoring of upcoming clinical data [19][21]. Section 4: Financial Projections - Revenue forecasts for the company are optimistic, with projected revenues of 2.084 billion, 2.876 billion, and 4.663 billion CNY for 2025, 2026, and 2027 respectively [5][7]. - The company is expected to achieve profitability by 2027, with a projected net profit of 561 million CNY [5].

Company Overview - Shun Teng International Holdings Limited is a publicly listed company in Hong Kong, previously known as Yu Yao Tang Group Holdings Limited, and has been listed on the Hong Kong Stock Exchange since October 11, 2013 [3] - The company primarily engages in the sales, marketing, and distribution of health and beauty supplements and products in Hong Kong and China [3] Financial Performance - As of March 31, 2025, Shun Teng International reported total revenue of 189 million yuan, a year-on-year decrease of 12.96% [2] - The company recorded a net profit attributable to shareholders of -33.4461 million yuan, representing a significant year-on-year decline of 6447.29% [2] - The gross profit margin stood at 77.03%, while the debt-to-asset ratio was 53.15% [2] Stock Performance - As of July 28, the stock price of Shun Teng International closed at 0.032 HKD per share, reflecting an increase of 10.34% with a trading volume of 732,000 shares and a turnover of 23,100 HKD [1] - Over the past month, the stock has experienced a cumulative decline of 9.38%, and since the beginning of the year, it has decreased by 6.45%, underperforming the Hang Seng Index, which has risen by 26.56% [2] Industry Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 3.12 times, with a median of 6.67 times [2] - Shun Teng International's P/E ratio is -2.49 times, ranking 146th in the industry [2] - Comparatively, other companies in the industry have the following P/E ratios: Other Precision Pharmaceuticals at 1.27 times, Kingsray Biotechnology at 1.69 times, Dongrui Pharmaceutical at 3.35 times, Jilin Changlong Pharmaceutical at 6.39 times, and Dajian Health International at 6.67 times [2]